May 6, 2008 -
United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary
Lung Rx, Inc. announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the
American Thoracic Society (ATS), to be held in Toronto, Ontario, beginning May 16th and ending May 21, 2008,
including the first public presentation of the full data set from the TRIUMPH-1 study of inhaled treprostinil...
United Therapeutics Corporation's Press Release -
